The ADC Manufacturing & CDMO market is growing rapidly due to the increasing development and commercialization of antibody-drug conjugates (ADCs) for cancer treatment. The market is expanding due to the increasing number of ADC candidates in clinical trials, rising regulatory approvals, and the growing demand for specialized manufacturing capabilities. Advanced conjugation technologies, high-potency manufacturing facilities and regulatory expertise are driving an increase in pharmaceutical and biotechnology companies outsourcing ADC development and production to specialized CDMOs, in order to cut capital investments.
ADC Manufacturing & CDMO Market Trends & Forecast
According to a research study published by Knowledge Sourcing Intelligence (KSI), the ADC Manufacturing & CDMO Market will expand from USD 5.15 billion in 2026 to USD 10.49 billion in 2031 at a CAGR of 15.3% during the forecast period.
The commercialization of antibody-drug conjugates (ADCs) with impressive clinical and commercial successes, the outsourcing of complex biologics manufacturing activities, and the demand for specialized contract development and manufacturing services (CDMOs) are set to fuel the ADC Manufacturing & CDMO market during the forecast period. With the number of ADC candidates making it through clinical pipelines and regulatory submissions, there is a growing need for integrated manufacturing capabilities, including antibody production, linker synthesis, payload manufacturing, conjugation, fill-finish, and analytical testing.
The improvements in conjugation technologies, handling of high-potency active pharmaceutical ingredients (HPAPI), and scalable manufacturing platforms are enhancing production efficiency and advancing next-generation ADC therapies to commercialization. As more pharmaceutical and biotechnology firms prefer to rely on specialized CDMOs to handle various components of the development process and manage lower capital expenditure, reduce development timelines and access technical expertise, this trend is driving market expansion. Further supportive of the market growth are the investments in dedicated ADC manufacturing facilities, the technologies for process optimization, and regulatory-compliant production infrastructure.
Request a free sample copy or view the report summary: ADC Manufacturing & CDMO Market Report
ADC Manufacturing & CDMO Market Report Highlights
By Product Type, the monoclonal antibody component segment holds a significant market share owing to its critical role as the targeting backbone of ADC therapeutics. Linker technologies are seeing constant improvements in payload stability and controlled drug release and are seeing strong growth. Growing demand for cytotoxic payloads is fueled by the development of highly potent ADC candidates across a range of oncology indications by pharmaceutical companies.
Breast, lung, gastric, ovarian and other solid malignancies are the big drivers for solid tumors by indication, as many ADC therapies are in development and commercialization for these indications. Hematologic malignancies will continue to be an important area as the continued success with the use of ADCs in lymphoma, leukemia, and multiple myeloma. The others segment is growing as ADC drug development moves into other therapeutic areas, as well as into rare diseases.
Process development and clinical-scale manufacturing represent a significant portion by Stage of Development since there are a considerable number of ADC candidates at the preclinical and clinical development stages. Commercial-scale manufacturing is rapidly increasing because, with the growing number of regulatory approvals and product launches, large-scale manufacturing is now needed, and long-term supply contracts are needed.
Pharmaceutical and biotechnology companies are the largest users of ADCs, with outsourcing activities and growing needs for specialized ADC development and manufacturing skills. Research institutes also play an important role in the early stage of research collaboration, technology development, and translational studies to support ADC innovation.
The strong presence of the leading biopharmaceutical companies, CDMO service providers, a well-established CDMO segment, advanced manufacturing facilities, and high investment levels in oncology drug development are driving the North America ADC Manufacturing & CDMO market. Biologics manufacturing capacity is solid and the regulatory environment is favorable, and these factors help Europe retain a strong market share. Asia Pacific is projected to see the highest growth rates driven by rising biopharmaceutical investments, growing capacity of CDMOs, lower manufacturing costs, and growth in ADC development in countries like China, Japan, and South Korea.
ADC Manufacturing & CDMO Market Growth Drivers and Restraints
Growth Drivers:
Growing ADC Pipeline and Regulatory Approvals: The increasing number of ADC candidates moving into clinical development and the number of approvals continues to grow, creating a need for specialized manufacturing services, process development expertise, and commercial-scale production capabilities.
Rising Outsourcing by Pharmaceutical and Biotechnology Companies: Pharmaceutical and biotechnology companies are outsourcing to specialised CDMOs to gain access to advanced conjugation technologies, HPAPI handling and expertise, regulatory support and scalable manufacturing capacity without capital investment.
Restraints:
High Manufacturing Complexity and Cost: Specialized facilities, containment systems, advanced analytical capabilities, and highly skilled personnel are needed to produce ADC, which can be an expensive operation with high capital expenses.
Regulatory and Supply Chain Challenges: The regulatory requirements are very tight and complex technology transfer can lead to manufacturing limitations and slower time to commercialization.
ADC Manufacturing & CDMO Market Key Development
Investment: March 2026: Fujifilm invested in VALANX Biotech, an Austrian company specializing in site-specific conjugation technology, to further enhance its integrated antibody-drug conjugate (ADC) manufacturing platform, with commercial operations for end-to-end ADC services in Japan slated for 2027.
ADC Manufacturing & CDMO Market Segmentation
Knowledge Sourcing Intelligence has segmented the ADC Manufacturing & CDMO Market by product type, indication, stage of development, end-user, and geography:
ADC Manufacturing & CDMO Market By Product Type
Monoclonal Antibody Component
Linker Technology
Cytotoxic Payload
ADC Manufacturing & CDMO Market By Indication
Solid Tumor
Hematologic Malignancies
Others
ADC Manufacturing & CDMO Market By Stage of Development
Process Development & Clinical Scale
Commercial Scale
ADC Manufacturing & CDMO Market By End-User
Pharmaceutical & Biotechnology Companies
Research Institutes
ADC Manufacturing & CDMO Market By Region
North America
USA
Canada
Mexico
South America
Brazil
Argentina
Others
Europe
United Kingdom
Germany
France
Spain
Others
Middle East and Africa
Saudi Arabia
UAE
Others
Asia Pacific
China
India
Japan
South Korea
Indonesia
Thailand
Others
ADC Manufacturing & CDMO Market Key Players
F. Hoffmann-La Roche Ltd.
Pfizer Inc.
AstraZeneca plc
Daiichi Sankyo Company, Limited
AbbVie Inc.
Astellas Pharma Inc.
ImmunoGen, Inc.
Lonza Group AG
Samsung Biologics Co., Ltd.
Have questions?
More Press Releases
Modular AI Data Center Infrastructure Market to Reach USD 8.71 Billion by 2032, Driven by Rapid Deployment of Prefabricated AI Data Centers
The global modular AI data center infrastructure market is expanding as demand for high-density computing and faster AI infrastructure deployment increases. Prefabricated power modules, integrated cooling systems, and turnkey AI factory solutions are gaining traction among hyperscale operators and neocloud providers seeking scalable, energy-efficient infrastructure to support increasingly complex AI workloads.
Autonomous Vehicle Interior Market to Reach USD 26.53 Billion by 2031, Driven by AI-Powered Smart Cockpits and Human-Machine Interfaces
The global autonomous vehicle interior market is expanding as AI-powered smart cockpits, advanced human-machine interfaces, and occupant monitoring technologies transform in-vehicle experiences. Growing adoption of software-defined vehicle architectures, connected infotainment, and personalized cabin systems is creating opportunities for automotive suppliers as higher-level vehicle automation advances across global markets.
Data Center Silicon Photonics Market to Reach USD 23.1 Billion by 2032, Driven by AI Infrastructure and Co-Packaged Optics Adoption
The global data center silicon photonics market is expanding as AI infrastructure, hyperscale computing, and high-bandwidth networking increase demand for advanced optical connectivity. Innovations in co-packaged optics, photonic integrated circuits, and energy-efficient interconnects are creating growth opportunities, while manufacturing scalability, thermal management, and integration costs remain important industry considerations.
